Heart doctors are capturing images of the inside of heart arteries, helping them watch plaque respond to cholesterol drugs in ...

A new oral PCSK9 inhibitor, enlicitide, offers a daily pill option for lowering LDL-C, a key cardiovascular disease risk ...

Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.

Patients with statin resistance do not experience symptoms, Le noted. Instead, the problem is that statins do not lower LDL-C levels as much as they typically do. Instead of a 50% reduction, people ...

A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...

New review shows statins remain first-line therapy in MASLD, while PCSK9 inhibitors offer potential but require more evidence. Learn more about evolving treatment guidance.

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials Enlicitide had a favorable ...

Please provide your email address to receive an email when new articles are posted on . Less frequent anti-PCSK9 monoclonal antibody dosing is possible with recaticimab. When dosed every 12 weeks, the ...

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

PHILADELPHIA -- A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial. Recaticimab showed long-term ...

An experimental drug called enlicitide reduced levels of low-density lipoprotein (LDL), or “bad” cholesterol by almost 60% in ...